Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
Principais autores: | Maurer, J, Eugster, PJ, Collins, K, Vocat, C, Oke, J, Nicholson, B, Rakauskas, A, Grouzmann, E, Valerio, M |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Elsevier
2024
|
Registros relacionados
-
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection
por: Jonathan Maurer, et al.
Publicado em: (2024-08-01) -
Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
por: Alexander Meisel
Publicado em: (2019-12-01) -
Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men
por: Nicolas Bourdillon, et al.
Publicado em: (2022-12-01) -
Biomarkers in early-stage colorectal cancer: ready for prime time?
por: Church, D, et al.
Publicado em: (2012) -
REBOA: is it ready for prime time?
por: Jay Doucet, et al.